Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Gross Margin (2023 - 2025)

Iovance Biotherapeutics has reported Gross Margin over the past 3 years, most recently at 50.32% for Q4 2025.

  • Quarterly results put Gross Margin at 50.32% for Q4 2025, up 159.0% from a year ago — trailing twelve months through Dec 2025 was 28.66% (down 556.0% YoY), and the annual figure for FY2025 was 34.28%, down 889.0%.
  • Gross Margin for Q4 2025 was 50.32% at Iovance Biotherapeutics, up from 42.96% in the prior quarter.
  • Over the last five years, Gross Margin for IOVA hit a ceiling of 1211.41% in Q4 2023 and a floor of 915.52% in Q1 2024.
  • Median Gross Margin over the past 3 years was 5.48% (2025), compared with a mean of 99.9%.
  • Biggest five-year swings in Gross Margin: plummeted -116269bps in 2024 and later skyrocketed 91468bps in 2025.
  • Iovance Biotherapeutics' Gross Margin stood at 1211.41% in 2023, then crashed by -96bps to 48.72% in 2024, then rose by 3bps to 50.32% in 2025.
  • The last three reported values for Gross Margin were 50.32% (Q4 2025), 42.96% (Q3 2025), and 5.48% (Q2 2025) per Business Quant data.